Multiple Sclerosis Drugs Market Size, Share & Industry Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection {Intramuscular, Subcutaneous, and Intravenous}), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2024-2032

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2023

Estimated Year

2024

Forecast Period

2024-2032

Historical Period

2019-2022

Growth Rate

CAGR of 7.9% from 2024-2032

Unit

Value (USD Billion)

Segmentation

By Drug Class

• Immunomodulators


• Immunosuppressants


• Interferons


• Others

By Route of Administration

• Oral


• Injection




• Intramuscular


• Subcutaneous


• Intravenous

By Distribution Channel

• Hospital Pharmacy


• Retail Pharmacy


• Online Pharmacy

By Geography

• North America (By Drug Class, by Route of Administration, by Distribution Channel, and by Country)




• U.S.


• Canada




• Europe (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)




• U.K.


• Germany


• France


• Italy


• Spain


• Scandinavia


• Rest of Europe




• Asia Pacific (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)




• Japan


• China


• India


• Australia


• Southeast Asia


• Rest of Asia Pacific




• Latin America (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)




• Brazil


• Mexico


• Rest of Latin America




• Middle East & Africa (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)




• South Africa


• GCC


• Rest of the Middle East & Africa